Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Peritoneal Cancer
Ovarian Cancer

Interventions: Drug: carboplatin
Drug: pralatrexate
Drug: Folic Acid
Drug: Vitamin B12 Injection

First Posted Date: 2010-08-26

Last Posted Date: 2018-01-19

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 50

Registration Number: NCT01188876

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

Phase 1

Active, not recruiting

Conditions: Advanced Cancer

Interventions: Drug: Temsirolimus
Drug: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin
Drug: Sorafenib

First Posted Date: 2010-08-23

Last Posted Date: 2024-11-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 278

Registration Number: NCT01187199

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma

Phase 2

Terminated

Conditions: Gastroesophageal Adenocarcinoma
Adenocarcinoma of the Distal Esophagus
Adenocarcinomas of the Gastroesophageal Junction
Adenocarcinoma of the Proximal Stomach

Interventions: Drug: Panitumumab
Drug: Paclitaxel
Drug: Carboplatin
Drug: 5FU

First Posted Date: 2010-08-17

Last Posted Date: 2012-12-03

Lead Sponsor: Accelerated Community Oncology Research Network

Target Recruit Count: 1

Registration Number: NCT01182610

Locations: 🇺🇸
Clopton Clinic, Jonesboro, Arkansas, United States

A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery

Phase 1

Completed

Conditions: Cancer of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Cancer of the Stomach

Interventions: Drug: Vandetanib
Drug: 5 Fluorouracil (FU)
Drug: Carboplatin
Drug: Paclitaxel
Radiation: External Beam Radiation Therapy (RT)

First Posted Date: 2010-08-17

Last Posted Date: 2021-01-22

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 9

Registration Number: NCT01183559

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Trientine and Carboplatin in Advanced Malignancies

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Trientine MTD
Drug: Trientine
Drug: Carboplatin MTD
Drug: Carboplatin
Other: PK Testing

First Posted Date: 2010-08-09

Last Posted Date: 2015-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 56

Registration Number: NCT01178112

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Axitinib
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2010-08-03

Last Posted Date: 2018-06-08

Lead Sponsor: Adil Daud

Target Recruit Count: 40

Registration Number: NCT01174238

Locations: 🇺🇸
Cutaneous Onocology Group at the Helen Dillar Family Comprehensive Cancer Center UCSF, San Francisco, California, United States

High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy

Phase 2

Conditions: Brain and Central Nervous System Tumors
Extragonadal Germ Cell Tumor
Testicular Germ Cell Tumor

First Posted Date: 2010-07-30

Last Posted Date: 2013-08-12

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 47

Registration Number: NCT01172912

Locations: 🇮🇹
Fondazione Istituto Nazionale dei Tumori, Milan, Italy

Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients

Phase 2

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2010-07-29

Last Posted Date: 2023-11-29

Lead Sponsor: University of Chicago

Target Recruit Count: 34

Registration Number: NCT01172470

Locations: 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States

Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

Phase 1

Completed

Conditions: Hodgkin's Lymphoma

Interventions: Drug: Panobinostat
Drug: Ifosfamide
Drug: Mesna
Drug: Carboplatin
Drug: Etoposide
Drug: Pegfilgrastim

First Posted Date: 2010-07-26

Last Posted Date: 2021-01-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT01169636

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer

Phase 2

Terminated

Conditions: Breast Neoplasms

Interventions: Drug: Cisplatin
Drug: Carboplatin
Radiation: Radiation therapy
Procedure: Mastectomy (recommended but not mandatory)

First Posted Date: 2010-07-22

Last Posted Date: 2016-12-30

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 10

Registration Number: NCT01167192

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy